Cencora, Inc. (COR)

Over the past six months, Cencora's stock has risen by 13.4%. Key events impacting the stock include the Q4 2025 earnings report, which led to a 2.8% stock increase, and the Q2 CY2025 earnings report, which exceeded Wall Street's revenue expectations. The company recently declared a quarterly dividend increase to $0.60 per share. Walgreens Boots Alliance has been selling down its stake in Cencora, which was seen as removing a selling overhang.

While specific detailed demand seasonality is not explicitly provided, Cencora benefits from sustained pharmaceutical utilization trends, particularly within specialty drugs. Strong demand exists across oncology and retina, and the boom in GLP-1s is also driving demand. The company's seasonality profile measures the change in price over time on average for each calendar month, indicating how frequently each month closes higher than the one before it.

Cencora, Inc., formerly AmerisourceBergen Corporation, is a global pharmaceutical solutions organization operating within the Health Care sector. The company plays a critical role in the healthcare supply chain through pharmaceutical distribution and related services, including the distribution of generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and vaccines. Cencora serves a broad spectrum of the healthcare ecosystem, including pharmaceutical and biotechnology manufacturers, pharmacies, hospitals, health systems, and specialty providers.

Cencora operates in over 50 countries with headquarters in Conshohocken, Pennsylvania. Its operations are segmented into U.S. Healthcare Solutions, serving hospitals, pharmacies, clinics, and specialty providers across the United States, and International Healthcare Solutions, with a significant pan-European pharmaceutical presence through its Alliance Healthcare division.

Cencora's brand reputation has been influenced by challenges, including a cyber incident that exposed patient information and historical controversies related to the opioid epidemic. Despite these challenges, recent market sentiment analysis suggests a very positive media sentiment, with analysts generally holding a bullish view on Cencora.

Cencora's ownership structure is primarily institutional, with institutional shareholders holding approximately 91.86% of the stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Insider ownership is relatively low, around 0.4%, with executives having sold shares over the past year.